Literature DB >> 28275474

Effects of leukotriene D4 nasal challenge on bronchial responsiveness and inflammation in asthmatic patients with allergic rhinitis.

Zheng Zhu1, Yanqing Xie1, Weijie Guan1, Yi Gao1, Rongquan Huang1, Shu Xia1, Wenhua Jian1, Zhiyu Liang1, Jinping Zheng1.   

Abstract

BACKGROUND: In asthmatic patients with allergic rhinitis (AR), increased cysteinyl leukotrienes (CysLTs) production in the secretion of nasal mucosa has been associated with greater bronchial hyperresponsiveness (BHR) after nasal allergen challenge. However, the role of CysLTs in eliciting BHR after nasal allergen challenge has not been evaluated. The aim of this study is to evaluate the effect of LTD4 nasal challenge on BHR and inflammation in asthmatic patients with AR.
METHODS: In this self-controlled study, fifteen eligible consecutively recruited subjects underwent methacholine (Mch) bronchial provocation test before and 30 minutes after LTD4 nasal provocation test. The cumulative concentration of LTD4 inducing a 60% increase in nasal airway resistance (PC60NAR) was calculated. The mean values of cumulative doses inducing a 20% decrease in forced expiratory flow in one second (PD20FEV1) for Mch before and after nasal challenge were compared. Fractional exhaled nitric oxide (FeNO), differential inflammatory cell counts in nasal lavage and induced sputum before and after nasal challenge were compared.
RESULTS: House dust mites were the major allergens accounting for 10/15 (66.7%) of asthmatic patients with AR. The PC60NAR for LT was (8.39±3.48)×10-3 mg·mL-1. The PD20FEV1 before and after nasal challenge was 3.05±3.81 and 2.70±3.81 µmol, respectively (P=0.45). The percentages of eosinophils were (38.36±23.14)% and (45.70±24.86)% in nasal lavage, and (17.51±11.05)% and (24.29±16.52)% in induced sputum before and 24 hours after nasal challenge. The neutrophil counts were (60.64±23.14)% and (53.30±24.46)% in nasal lavage, and (53.83±23.27)% and (56.19±22.28)% in induced sputum before and 24 hours after nasal challenge. The values of FeNO were 40 [35] and 43 [30] ppb before and 24 hours after nasal challenge. No severe adverse effects were reported during the tests.
CONCLUSIONS: Although most asthmatic patients with AR were sensitive to LTD4 nasal challenge, LTD4 nasal provocation tests do not confer any major effect on BHR. LTD4 might not play a vital role in eliciting bronchial responsiveness induced by nasal allergen challenge.

Entities:  

Keywords:  Leukotriene D4 (LTD4); airway hyperresponsiveness; allergic rhinitis (AR); asthma; bronchial provocation

Year:  2017        PMID: 28275474      PMCID: PMC5334110          DOI: 10.21037/jtd.2017.02.36

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  28 in total

1.  [Application of the nasal provocation test on diseases of the upper airways. Position paper of the German Society for Allergology and Clinical Immunology (ENT Section) in cooperation with the Working Team for Clinical Immunology].

Authors:  H Riechelmann; C Bachert; O Goldschmidt; B Hauswald; L Klimek; W W Schlenter; A J Tasman; M Wagenmann
Journal:  Laryngorhinootologie       Date:  2003-03       Impact factor: 1.057

2.  Effect of inhaled leukotriene D4 on airway eosinophilia and airway hyperresponsiveness in asthmatic subjects.

Authors:  A Mulder; G M Gauvreau; R M Watson; P M O'byrne
Journal:  Am J Respir Crit Care Med       Date:  1999-05       Impact factor: 21.405

3.  Efficacy and safety of montelukast in adults with asthma and allergic rhinitis.

Authors:  J Chr Virchow; C Bachert
Journal:  Respir Med       Date:  2006-04-12       Impact factor: 3.415

Review 4.  Symptom severity assessment of allergic rhinitis: part 1.

Authors:  Sheldon L Spector; Richard A Nicklas; Jean A Chapman; I Leonard Bernstein; William E Berger; Joann Blessing-Moore; Mark S Dykewicz; Stanley M Fineman; Rufus E Lee; James T Li; Jay M Portnoy; Diane E Schuller; David Lang; Stephen A Tilles
Journal:  Ann Allergy Asthma Immunol       Date:  2003-08       Impact factor: 6.347

Review 5.  Allergic rhinitis and asthma: how important is the link?

Authors:  J Corren
Journal:  J Allergy Clin Immunol       Date:  1997-02       Impact factor: 10.793

6.  Changes in airway inflammation following nasal allergic challenge in patients with seasonal rhinitis.

Authors:  M Bonay; C Neukirch; M Grandsaigne; V Leçon-Malas; P Ravaud; M Dehoux; M Aubier
Journal:  Allergy       Date:  2006-01       Impact factor: 13.146

Review 7.  One airway, one disease.

Authors:  J Grossman
Journal:  Chest       Date:  1997-02       Impact factor: 9.410

8.  Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans.

Authors:  H Bisgaard; P Olsson; M Bende
Journal:  Clin Allergy       Date:  1986-07

9.  Relationship between nasal hyperreactivity, mediators and eosinophils in patients with perennial allergic rhinitis and controls.

Authors:  C de Graaf-in t Veld; I M Garrelds; S Koenders; R Gerth van Wijk
Journal:  Clin Exp Allergy       Date:  1996-08       Impact factor: 5.018

10.  Effect of natural seasonal pollen exposure and repeated nasal allergen provocations on elevation of exhaled nitric oxide.

Authors:  K Bergmann-Hug; R Wirth; M Henseler; A Helbling; W J Pichler; B Schnyder
Journal:  Allergy       Date:  2009-07-21       Impact factor: 13.146

View more
  2 in total

1.  Montelukast, an Antagonist of Cysteinyl Leukotriene Signaling, Impairs Burn Wound Healing.

Authors:  Alan V Nguyen; Michelle D Bagood; Marilyn Wang; Sofia E Caryotakis; Glendalyn Smith; Shannon Yee; Haitao Shen; R Rivkah Isseroff; Athena M Soulika
Journal:  Plast Reconstr Surg       Date:  2022-05-10       Impact factor: 5.169

2.  Response of upper and lower airway inflammation to bronchial challenge with house dust mite in Chinese asthmatics: a pilot study.

Authors:  Zheng Zhu; Hongyu Wang; Yanqing Xie; Jiaying An; Qiurong Hu; Shu Xia; Jing Li; Paul O'Byrne; Jinping Zheng; Nanshan Zhong
Journal:  J Thorac Dis       Date:  2021-08       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.